Viome Life Sciences aims to make illness optional by predicting and preventing chronic diseases through a deeper understanding of an individual’s biology at a molecular level. They focus on prevention, diagnostics, and therapeutics using direct-to-consumer services and advanced technology.

Viome Life Sciences

Viome Life Sciences was founded in 2016 with a mission to make illness optional by predicting and preventing chronic diseases, cancers, and aging through a deeper understanding of an individual's biology at a molecular level.

Viome's Consumer Services (VIOME) provides the industry's only direct-to-consumer healthcare test that analyzes microbial and human gene expressions (mRNA), with technology exclusively licensed from Los Alamos National Lab, in order to provide individuals with health insights and the nutrition they need.

Our Health Sciences division focuses on key initiatives including prediction, early diagnostics, prognostics, and precision therapeutics to help people live a disease free life. With our state of the art artificial intelligence platform, we are able to analyze data from the world's largest and richest gene expression database in order to identify the root causes of chronic diseases, cancers, and aging and the mechanisms of action to be able to prevent and reverse them. 

Prediction: Using advanced AI methods to discover host/microbial biomarkers that predict the risk of developing severe chronic conditions, including cancers.

Early Diagnostics: Using host/microbial biomarkers to diagnose severe chronic conditions including cancers at the earliest possible stage. Early diagnosis will enable earlier treatment which often is associated with higher efficacy.

Prognostics: Leveraging host/microbial biomarkers to develop companion diagnostics to predict drug effectiveness and further improve responsiveness of patients by proposing AI-guided modulation of the microbiome.

Therapeutics: By targeting the root cause of specific chronic diseases with prophylactics or therapeutics such as drugs, monoclonal antibodies, vaccines, phages, or other appropriate modalities.

Today, we are very excited to announce the launch of our groundbreaking Oral Health Pro + CancerDetect solution, our first step in creating an ecosystem of care where each individual receives the highest level of personalized healthcare and professionals have the tools and insights they need to make it possible. Dental practices have already been onboarded and will be the first to deliver this cutting-edge solution to their patients! 

Now, the opportunity is open to all dental professionals who can visit https://www.viomepro.com/.

Our technology empowers dentists to customize treatments for individual patients, transforming them from healthcare providers to trusted allies in their patients' health journeys. 

For Oral Healthcare Professionals & Practices: Our Oral Health Pro + CancerDetect solution offers an intuitive, dual-interface system via our professional portal and for Patients through their Viome account. With this, ordering tests and retrieving patient information becomes a breeze for both you and your patients. Our solution integrates seamlessly into their workflows, offering an array of benefits - from free educational resources to boosting patient retention and loyalty - all while maintaining optimal care without infringing upon their valuable chair time.

For Patients: Patients receive a home-delivered kit from Viome, allowing them to send their saliva samples with ease. The detailed Oral Health Pro report provides a comprehensive view of their oral health, enabling dentists to tailor highly personalized treatment plans.


Learn more at http://www.viomepro.com 
Or email us at OralCarePro@viome.com

#ViomeLifeSciences #Viome #OralHealthPro #CancerDetect #oralhealth #oralcancer #throatcancer #ViomePRO #healthcare #technology #health

“Stop dreaming small!”

Amazing conversation!  

Thank you Naveen Jain & Jay Shetty

At Viome, we analyze the biochemical activities within your gut microbiome with metatranscriptomics (RNA analysis) and AI algorithms, and create tailored nutritional plans to fit the unique needs of each individual. When we studied the difference between people who took advantage of our precision supplements and people who didn’t, we found that 77.3% of those who did improved their depression symptoms compared with 20.8% of those who didn’t. This shows that precision nutrition can be as much of a factor in your mental health as your physical health. Our latest pre-print on this study is just out 

https://lnkd.in/eEFh77HC

msh id	COM:VIOMELIFESCIENCES
symbol	-
name	Viome Life Sciences
homepage url	https://viomelifesciences.com
country	US
sector	Healthcare & Health Services
industry	Healthcare & Health Services
market	PRIVATE
employee count	25
crunchbase url	https://www.crunchbase.com/organization/viome-life-sciences
linkedin url	https://www.linkedin.com/company/viomelifesciences
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:VIOMELIFESCIENCES

Viome Life Sciences

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-